ELQ-300

ELQ-300
Names
IUPAC name
6-chloro-7-methoxy-2-methyl-3-{4-[4-(trifluoromethoxy)phenoxy]phenyl}quinolin-4(1H)-one
Identifiers
3D model (Jmol) Interactive image
ChemSpider 28540481
Properties
C24H17ClF3NO4
Molar mass 475.844
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references

ELQ-300 is an experimental antimalarial medication. It is an endochin-like quinolone and the first in a new class of antimalarials known as quinolone-3-diarylethers.[1]

ELQ-300 acts as an inhibitor of the mitochondrial cytochrome bc1 complex (complex III in the electron transport chain).[1] In preclinical studies with mice, it was found to be highly active against Plasmodium falciparum and Plasmodium vivax at all life cycle stages that play a role in the transmission of malaria, and to have good oral bioavailability.[1]

References

  1. 1 2 3 Nilsen A; et al. (2013). "Quinolone-3-diarylethers: a new class of antimalarial drug". Science Translational Medicine. 5 (177): 177ra37. doi:10.1126/scitranslmed.3005029. ISSN 1946-6234.

Further reading

This article is issued from Wikipedia - version of the 7/7/2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.